Cited by 698

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Structure−Brain Exposure Relationships

Hitchcock, Stephen A., Pennington, Lewis D.·2006·Journal of Medicinal Chemistry

Open this paper in CoChat — free account

Abstract

ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTStructure−Brain Exposure RelationshipsStephen A. Hitchcock and Lewis D. PenningtonView Author Information Chemistry Research & Discovery, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799 Cite this: J. Med. Chem. 2006, 49, 26, 7559–7583Publication Date (Web):December 5, 2006Publication History Received30 May 2006Published online5 December 2006Published inissue 1 December 2006https://pubs.acs.org/doi/10.1021/jm060642ihttps://doi.org/10.1021/jm060642ireview-articleACS PublicationsCopyright © 2006 American Chemical SocietyRequest reuse permissionsArticle Views8747Altmetric-Citations544LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antibiotic resistance,Central nervous system,Permeability,Pharmaceuticals,Rodent models Get e-Alerts

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/jm060642i

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Blood-brain barrier drug targeting: the future of brain drug development.
Pardridge, W. M. (2003) · Molecular Interventions · doi:10.1124/mi.3.2.90 · Cited by 570
ABC Transporters and the Blood-Brain Barrier
Begley, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384844 · Cited by 545
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists
Young, R. C., Mitchell, R. C., Brown, T. H., Ganellin, C. R., Griffiths, R., Jones, M., Rana, K. K., Saunders, D., & Smith, I. R. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00398a028 · Cited by 521
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Delivery of peptides and proteins through the blood–brain barrier
Bickel, U., Yoshikawa, T., & Pardridge, W. M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00139-3 · Cited by 481
THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL
Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design
Hansch, C., Björkroth, J. P., & Leo, A. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760902 · Cited by 438
In vitro models for the blood–brain barrier
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R. D., Lindmark, T., Mabondzo, A., Nilsson, J. E., Raub, T. J., et al. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.06.011 · Cited by 394
Transporter-Mediated Permeation of Drugs Across the Blood–Brain Barrier
Tamai, I., & Tsuji, A. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200011)89:11<1371::aid-jps1>3.0.co;2-d · Cited by 363
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrier
Wang, Q., Rager, J. D., Weinstein, K., Kardos, P. S., Dobson, G. L., Li, J., & Hidalgo, I. J. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.10.007 · Cited by 348
Structure–activity relationship of P-glycoprotein substrates and modifiers
Seelig, A., & Landwojtowicz, E. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00177-9 · Cited by 275
The Role of Drug Transporters at the Blood-Brain Barrier
de Boer, A. G., van der Sandt, I. C. J., & Gaillard, P. J. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140204 · Cited by 238
Active efflux across the blood-brain barrier: Role of the solute carrier family
Kusuhara, H., & Sugiyama, Y. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.73 · Cited by 236
Tissue Concentrations of Clozapine and its Metabolites in the Rat
Baldessarini, R. J., Centorrino, F., Flood, J. G., Volpicelli, S. A., Huston-Lyons, D., & Cohen, B. M. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.50 · Cited by 233
Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography
Laruelle, M. (2003) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2003.09.009 · Cited by 228
The rise of PAMPA
Avdeef, A. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.325 · Cited by 222
RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE
Maurer, T. S., DeBartolo, D. B., Tess, D. A., & Scott, D. O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001222 · Cited by 214
Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems
Tsuji, A. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.54 · Cited by 209
Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation
Lleó, A., Berezovska, O., Herl, L., Raju, S., Deng, A., Bacskai, B. J., Frosch, M. P., Irizarry, M., & Hyman, B. T. (2004) · Nature Medicine · doi:10.1038/nm1112 · Cited by 198
Drug metabolizing enzymes in the brain and cerebral microvessels
Minn, A., Ghersi-Egea, J.-F., Perrin, R., Leininger, B., & Siest, G. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90020-9 · Cited by 183
Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain
Summerfield, S. G., Stevens, A. J., Cutler, L., del Carmen Osuna, M., Hammond, B., Tang, S.-P., Hersey, A., Spalding, D. J., & Jeffrey, P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092916 · Cited by 175
Carrier-mediated or specialized transport of drugs across the blood–brain barrier
Tsuji, A., & Tamai, I. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00084-2 · Cited by 174
Blood–Brain Barrier Efflux Transport
Golden, P. L., & Pollack, G. M. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10424 · Cited by 174
Prediction of Drug Transport Through the Blood-Brain Barrier in Vivo: A Comparison Between Two in Vitro Cell Models
Lundquist, S., Renftel, M., Brillault, J., Fenart, L., Cecchelli, R., & Dehouck, M.-P. (2002) · Pharmaceutical Research · doi:10.1023/a:1016462205267 · Cited by 173
New approaches to in vitro models of blood–brain barrier drug transport
Terasaki, T., Ohtsuki, S., Hori, S., Takanaga, H., Nakashima, E., & Hosoya, K.-I. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02858-7 · Cited by 162
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor
Porter, R. A., Chan, W. N., Coulton, S., Johns, A., Hadley, M. S., Widdowson, K., Jerman, J. C., Brough, S. J., Coldwell, M., Smart, D., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00343-2 · Cited by 159
The factors that influence permeation across the blood–brain barrier
Abraham, M. H. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.12.004 · Cited by 154
Discovering Drugs through Biological Transformation: Role of Pharmacologically Active Metabolites in Drug Discovery
Fura, A., Shu, Y., Zhu, M., Hanson, R. L., Roongta, V. A., & Humphreys, W. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040066v · Cited by 151
Molecular Factors Influencing Drug Transfer across the Blood-Brain Barrier
Gratton, J. A., Abraham, M. H., Bradbury, M. W. B., & Chadha, H. S. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06072.x · Cited by 139
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs
Faassen, F. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00372-7 · Cited by 132
Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A Potent and Selective Dopamine D3 Receptor Antagonist with High Oral Bioavailability and CNS Penetration in the Rat
Stemp, G., Ashmeade, T. E., Branch, C. L., Hadley, M. S., Hunter, A. J., Johnson, C. N., Nash, D. J., Thewlis, K. M., Vong, A. K. K., Austin, N. E., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000090i · Cited by 131
Targeting drugs to the brain by redox chemical delivery systems
Prókai, L., Prókai-Tátrai, K., & Bodor, N. S. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200009)20:5<367::aid-med3>3.0.co;2-p · Cited by 125
Potential of Immobilized Artificial Membranes for Predicting Drug Penetration Across the Blood−Brain Barrier
Reichel, A., & Begley, D. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011904311149 · Cited by 122
In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind”
Goodwin, J. T., & Clark, D. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075705 · Cited by 113
Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42Secretion
Peretto, I., Redaelli, S., Parini, C., Zandi, M., Raveglia, L. F., Dondio, G. M., Fontanella, L., Misiano, P., Bigogno, C., Rizzi, A., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502541 · Cited by 111
Notch and the Amyloid Precursor Protein Are Cleaved by Similar γ-Secretase(s)
Kimberly, W. T., Esler, W. P., Ye, W., Ostaszewski, B. L., Gao, J., Diehl, T. S., Selkoe, D. J., & Wolfe, M. S. (2002) · Biochemistry · doi:10.1021/bi026888g · Cited by 107
Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic, Kynurenic and Diclophenamic Acids, Liable to Increase Neurotropic Activity
Manfredini, S., Pavan, B., Vertuani, S., Scaglianti, M., Compagnone, D., Biondi, C., Scatturin, A., Tanganelli, S., Ferraro, L., Prasad, P. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015556r · Cited by 102
Chemical Modification of Paclitaxel (Taxol) Reduces P-Glycoprotein Interactions and Increases Permeation across the Blood−Brain Barrier in Vitro and in Situ
Rice, A., Liu, Y., Michaelis, M. L., Himes, R. H., Georg, G. I., & Audus, K. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040114b · Cited by 99
Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice
Bender, D., Holschbach, M. H., & Stöcklin, G. (1994) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(94)90080-9 · Cited by 90
In Silico Prediction Models for Blood-Brain Barrier Permeation
Ecker, G. F., & Noe, C. R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365071 · Cited by 86
Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples
Chernet, E., Martin, L. J., Li, D., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.04.075 · Cited by 76
In silico ADME modelling: prediction models for blood–brain barrier permeation using a systematic variable selection method
Ramamurthi, N., & Gunturi, S. B. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.01.061 · Cited by 72
Active Transport of High-Affinity Choline and Nicotine Analogs into the Central Nervous System by the Blood-Brain Barrier Choline Transporter
Allen, D. D., Lockman, P. R., Roder, K. E., Dwoskin, L. P., & Crooks, P. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045856 · Cited by 68
Investigation into the correlation between the structure of hydroxypyridinones and blood–brain barrier permeability
Habgood, M. D., Liu, Z. D., Saghaei, L., Khodr, H., Abbott, J., & Hider, R. C. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00031-3 · Cited by 67
Relationship between Lipophilic Character and Anesthetic Activity
Glave, W. R., & Hansch, C. H. (1972) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600610420 · Cited by 67
Prodrugs for improved CNS delivery
Anderson, B. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00106-h · Cited by 65
A New Paclitaxel Photoaffinity Analog with a 3-(4-Benzoylphenyl)propanoyl Probe for Characterization of Drug-Binding Sites on Tubulin and P-Glycoprotein
Ojima, I., Duclos, O., Dormán, G., Simonot, B., Prestwich, G. D., Rao, S. P. S., Lerro, K. A., & Horwitz, S. B. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00020a001 · Cited by 51
Discovery of the α7 Nicotinic Acetylcholine Receptor Agonists. (R)-3‘-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5‘-[1‘,3‘]oxazolidin-2‘-one as a Novel, Potent, Selective, and Orally Bioavailable Ligand
Tatsumi, R., Fujio, M., Satoh, H., Katayama, J., Takanashi, S.-I., Hashimoto, K., & Tanaka, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049188d · Cited by 47
Peptide Transport and Delivery into the Central Nervous System
(2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8049-7 · Cited by 43
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia
Govek, S. P., Bonnefous, C., Hutchinson, J. H., Kamenecka, T. M., McQuiston, J., Pracitto, R., Zhao, L., Gardner, M. F., James, J. K., Daggett, L. P., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.017 · Cited by 43
Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling
Hansen, D. K., Scott, D. O., Otis, K. W., & Lunte, S. M. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(01)00542-8 · Cited by 41
In vivo EPR imaging by using an acyl-protected hydroxylamine to analyze intracerebral oxidative stress in rats after epileptic seizures
Yokoyama, H., Itoh, O., Aoyama, M., Obara, H., Ohya, H., & Kamada, H. (2000) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(00)00183-1 · Cited by 41
Hydrophilic, Pro-Drug Analogues of T138067 Are Efficacious in Controlling Tumor Growth In Vivo and Show a Decreased Ability To Cross the Blood Brain Barrier
Rubenstein, S. M., Baichwal, V. R., Beckmann, H., Clark, D. L., Frankmoelle, W. P., Roche, D., Santha, E., Schwender, S., Thoolen, M., Ye, Q., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000478d · Cited by 40
Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules
Manfredini, S., Vertuani, S., Pavan, B., Vitali, F., Scaglianti, M., Bortolotti, F., Biondi, C., Scatturin, A., Prasad, P. D., & Dalpiaz, A. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.043 · Cited by 37
Improved Brain Delivery of a Nonsteroidal Anti-Inflammatory Drug with a Synthetic Glyceride Ester: a Preliminary Attempt at a CNS Drug Delivery System for the Therapy of Alzheimer's Disease
Deguchi, Y., Hayashi, H., Fujii, S., Naito, T., Yokoyama, Y., Yamada, S., & Kimura, R. (2000) · Journal of drug targeting · doi:10.3109/10611860008997913 · Cited by 35
(+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the α7 nicotinic acetylcholine receptor
Tatsumi, R., Seio, K., Fujio, M., Katayama, J., Horikawa, T., Hashimoto, K., & Tanaka, H. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.091 · Cited by 25
Transport and Detoxication: Principles, Approaches, and Perspectives for Research on the Blood – Brain Barrier
Aigner, A. M., Wolf, S., & Gassen, H. G. (1997) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199700241 · Cited by 24
The Blood-Brain Barrier and Drug Delivery to the CNS
(2000) · CRC Press eBooks · doi:10.1201/9780367800529 · Cited by 18
Substituted thiazolamide coupled to a redox delivery system: a new γ-secretase inhibitor with enhanced pharmacokinetic profile
Laras, Y., Quéléver, G., Garino, C., Pietrancosta, N., Sheha, M. M., Bihel, F. J. ‐., Wolfe, M. S., & Kraus, J. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b415090b · Cited by 17
Evaluation of Blood-Brain Barrier Passage of a Muscarine M1 Agonist and a Series of Analogous Tetrahydropyridines Measured by In Vivo Microdialysis
Sveigaard, H. H., & Dalgaard, L. (2000) · Pharmaceutical Research · doi:10.1023/a:1007522626070 · Cited by 11

The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
Beno, B. R., Yeung, K.-S., Bartberger, M. D., Pennington, L. D., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501853m · Cited by 772
Self-citation
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477

See all 698

Authors: Hitchcock, S. A., & Pennington, L. D.
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2006-12-01
Volume: 49
Issue: 26
Pages: 7559-7583
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/jm060642i
OpenAlex: W2009979602
Cited by: 698
References: 68
FWCI: 15.03
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Structure−Brain Exposure Relationships

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources